西格列汀对2型糖尿病患者外周血miR-155、miR-146a及核因子κB表达影响的研究

Effect of Sitagliptin on expression of miR-155,miR-146a and NF-κB in peripheral blood in patients with type 2 diabetes mellitus

目的探讨西格列汀对T2DM患者外周血miR-155、miR-146a及核因子κB(NF-κB)表达的影响。方法选取2017年6月至2018年7月于本院内分泌科就诊的T2DM患者100例,随机分为对照组(Con,常规口服降糖药)54例和试验组(Sit,在常规口服降糖药基础上加用西格列汀)46例。分别于治疗前及治疗3个月后采用RT-PCR检测外周血miR-155、miR-146a、NF-κB水平。结果治疗后两组外周血miR-155、NF-κB水平降低,miR-146a水平升高(P<0.05或P<0.01)。Sit组miR-155、miR-146a、NF-κB变化幅度较Con组明显[(0.49±0.18)vs(0.29±0.10),(0.71±0.24)vs(0.35±0.11),(0.47±0.14)vs(0.16±0.05),P<0.05]。Pearson相关分析显示,miR-155与BMI、HbA1c、HOMA-IR及NF-κB呈正相关(P<0.05),miR-146a与BMI、HbA1c及NF-κB呈负相关(P<0.05)。结论西格列汀可能具有调节miR-155、miR-146a、NF-κB表达的作用。

Objective To investigate the effect of Sitagliptin on the expression of miR-155,miR-146 a and NF-κB in peripheral blood in patients with type 2 diabetes mellitus(T2DM).Methods A total of100 T2DM patients cared at the Wuhan Fourth Hospital were recruited in this study and randomly divided into control group(Con,n=54)(conventional oral antidiabetic agents)and experimental group(Sit,n=45)(Sitagliptin was added on conventional oral antidiabetic agents).The expression of miR-155,miR146 a and NF-κB in peripheral blood were detected by real-time quantitative PCR(RT-PCR)before and after treatment for 3 months.Results After treatment,the levels of miR-155 and NF-κB in peripheral blood were decreased in the two groups,while the levels of miR-146 a was increased(P<0.05 or P<0.01).The changes of the above indexes was more obvious in Sit group than in Con group[miR-155(0.49±0.18)vs(0.29±0.10),miR-146 a(0.71±0.24)vs(0.35±0.11),NF-κB(0.47±0.14)vs(0.16±0.05),P<0.05].The level of miR-155 was positively correlated with BMI,HbA1 c,HOMA-IR and NF-κB(P<0.05),and the level of miR-146 a was negatively correlated with BMI,HbA1 c and NF-κB(P<0.05).Conclusion Sitagliptin may have the effect of regulating the expression of miR-155,miR-146 a and NF-kB.